ArticleNature communications2023

Treatment of monogenic and digenic dominant genetic hearing loss by CRISPR-Cas9 ribonucleoprotein delivery in vivo.

Yong Tao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.